Cambridge Healthtech Institute’s 4th Annual

Adoptive T-Cell Therapy

Effective and Unconventional Strategies

21-22 March 2019

 

The therapeutic potential of adoptive T-cell therapy was first acknowledged a couple decades ago, but it was only last year that we transformed adoptive T-cell therapy into a viable therapeutic option for patients by the two CAR T-cell therapies approved by the FDA. Although this is a very exciting time for adoptive T-cell therapy, there is still much to be done to reach its full potential. Cambridge Healthtech Institute’s 4th Annual Adoptive T-Cell Therapy will gather experts in the field to address clinical progress, discuss strategies to reduce toxicity, increase efficacy, production and cost-effectiveness, along with showcasing emerging unconventional T-cell therapies.

Preliminary Agenda

NEXT GENERATION T-CELL THERAPY

NK Fighter CAR T Cells

Mark Exley, Vice President, Cellular Immunology, Agenus

New Horizons for Adoptive T Cell Therapy

Phil Darcy, PhD, Professor, NHMRC Principal Research Fellow, Laboratory Head Cancer Immunotherapy, Peter MacCallum Cancer Centre, Australia

TILs AND TCRs

TCR-Engineered T Cells Combined with T Cell Co-Stimulation to Treat Solid Tumors

Reno Debets, PhD, Associate Professor, Laboratory of Tumor Immunology, PI, Medical Oncology Erasmus MC Cancer Institute

Preclinical Data and Clinical Plan for Developing Tumour Infiltrating Lymphocytes (TIL) for Solid Tumor Indication

Robert Hawkins, MB BS, MRCP, PhD, FRCP, Cancer Research UK Professor, Medical Oncology, University of Manchester & Honorary Consultant, Medical Oncology, Christie Hospital

UNIVERSAL CAR T

First Allogeneic CAR T-Cell Therapy Trial/ CYAD 101

David Gilham, Vice President Research and Development, Celyad

ADVANCES IN CLINICAL TRIALS

CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications

Hinrich Abken, MD, PhD, Professor, Cancer Genetics and Immunology, University of Cologne

Targeting Cytokines to the Tumor Vasculature to Improve Therapeutic Efficacy of Adoptive T Cell Therapy

Anna Mondino, Head, Lymphocyte Activation Unit, Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute

PANEL DISCUSSION: Safety Management of Cytokine release and Toxicity

Moderator: Michaela Sharpe, PhD, Head of Nonclinical Safety and Immunotherapy Strategy, Cell and Gene Therapy Catapult

UK Novel and Ground-Breaking Government Investment in the Advanced Therapy Treatment Centres

Jacqueline Barry, PhD, Chief Clinical Officer, Cell and Gene Therapy Catapult




For more details on the conference, please contact:
Emily Le

Conference Producer

Cambridge Healthtech Institute

Phone: (+1) 781-247-1812
Email: ele@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com